← All trials
NCT04656535
Early Phase 1Interventional
Exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies).
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Jul 31, 2023
- First posted
- Dec 7, 2020
- Last posted
- Dec 7, 2020
- Enrollment
- 46
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Yale UniversityLead sponsor
- Yale UniversityReponsible party - principal investigator
- Arcus Biosciences, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.